Dianthus Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2015 | — | $-289.0K | $500.0K |
| Dec 2016 | — | $-8.9M | $4.5M |
| Jun 2017 | — | — | $63.8M |
| Sep 2017 | — | — | $60.0M |
| Dec 2017 | — | $-42.1M | $51.4M |
| Mar 2018 | — | $-51.9M | $41.5M |
| Jun 2018 | — | $172.2M | $173.4M |
| Sep 2018 | — | $159.8M | $159.7M |
| Dec 2018 | — | $145.6M | $58.3M |
| Mar 2019 | — | $134.0M | $31.2M |
| Jun 2019 | — | $179.6M | $33.1M |
| Sep 2019 | — | $161.5M | $85.5M |
| Dec 2019 | — | $141.2M | $65.1M |
| Mar 2020 | — | $125.4M | $74.9M |
| Jun 2020 | — | $173.9M | $136.3M |
| Sep 2020 | — | $158.6M | $141.7M |
| Dec 2020 | — | $143.9M | $58.2M |
| Mar 2021 | — | $129.1M | $49.3M |
| Jun 2021 | — | $202.9M | $155.0M |
| Sep 2021 | — | $189.7M | $157.5M |
| Dec 2021 | — | $-17.2M | $131.7M |
| Mar 2022 | — | $-22.1M | $71.8M |
| Jun 2022 | — | $-27.5M | $54.8M |
| Sep 2022 | — | $-34.8M | $36.9M |
| Dec 2022 | — | $-44.4M | $15.4M |
| Mar 2023 | — | $-50.8M | $23.2M |
| Jun 2023 | — | $-61.5M | $40.3M |
| Sep 2023 | — | $178.4M | $157.3M |
| Dec 2023 | — | $168.9M | $132.3M |
| Mar 2024 | — | $372.7M | $329.7M |
| Jun 2024 | — | $358.2M | $314.2M |
| Sep 2024 | — | $337.9M | $33.7M |
| Dec 2024 | — | $352.5M | $22.8M |
| Mar 2025 | — | $328.6M | $10.1M |
| Jun 2025 | — | $303.1M | $13.2M |
| Sep 2025 | — | $546.5M | $56.0M |
| Dec 2025 | — | $493.4M | $51.1M |
| Mar 2026 | — | $1.20B | $627.7M |
| Jun 2026 | — | $1.17B | $110.5M |